Table 1

Baseline demographic and clinical characteristics of the study participants.

Characteristics	N=57
Sex, N (%)
Male	57 (100.0)
Age, mean±SD	34.6±19.0
Age group (yr), N (%)
<6	3 (5.3)
≥6 to <12	6 (10.5)
≥12 to <19	4 (7.0)
≥19	44 (77.2)
BMI (kg/m²), mean±SDa)	24.0±3.7
Hepatic impairment, N (%)
Yes	6 (10.5)
No	51 (89.5)
History of allergic reactions, N (%)
Yes	1 (1.8)
No	55 (96.5)
Unknown	1 (1.8)
Family history of inhibitor development, N (%)
Yes	3 (5.3)
No	51 (89.5)
Unknown	3 (5.3)
Bleeding episodes by severity (number) within the last 12 mo (mean±SD)
Minor (N=41)	22.4±24.8
Moderate (N=14)	2.5±3.1
Major (N=4)	1.3±0.5
Use of FIX before Rixubis treatment, N (%)
Yes	54 (94.7)
No	3 (5.3)
Total number of days of FIX product use after hemophilia B diagnosis, N (%)b)
1–4 days	4 (7.4)
5–20 days	4 (7.4)
21–50 days	4 (7.4)
51–100 days	16 (29.6)
101–150 days	1 (1.9)
>150 days	24 (44.4)
Current medical status, N (%)
Acquired immunodeficiency syndrome	3 (5.3)
Chronic hepatitis C	3 (5.3)
Chronic hepatitis B	2 (3.5)
Hepatitis C	1 (1.8)
Hypertension	4 (7.0)
Arthralgia	1 (1.8)
Hemophilic arthropathy	1 (1.8)
Osteonecrosis	1 (1.8)
Arthroscopy	1 (1.8)
Diabetes mellitus	1 (1.8)
Bronchitis chronic	1 (1.8)
Rehabilitation therapy	1 (1.8)
Duration of hemophilia B (yr), mean±SDb)	18.1±10.2

^a)N=48 (data are missing for nine patients). ^b)N=53 (data are missing for four patients).

Abbreviations: BMI, body mass index; FIX, factor IX; SD, standard deviation.